Tero Aittokallio
PhD
teanai@utu.fi Tykistökatu 6 A Turku ORCID-tunniste: https://orcid.org/orcid.org/0000-0002-0886-9769 |
Tero Aittokallio received his PhD in Applied Mathematics from the University of Turku in 2001, under the supervision of Prof. Mats Gyllenberg. He then did his post-doctoral training in the Systems Biology Lab at the Institut Pasteur (2006-2007), with Dr. Benno Schwikowski, where he focused on network biology applications using high-throughput experimental assays and network analysis tools such as Cytoscape. In 2007, Dr. Aittokallio launched his independent career as a principal investigator in the Turku Biomathematics Research Group, where he received a five-year appointment as an Academy of Finland Research Fellow (2007-2012). Tero Aittokallio joined Institute for Molecular Medicine Finland (FIMM) as EMBL Group Leader in the fall of 2011, and was selected as Professor of Statistics and Applied Mathematics at University of Turku in 2015.
Aittokallio's research group focuses on developing and applying integrated computational-experimental approaches to tackle biomedical questions, such as how genes function as interaction networks to carry out and regulate cellular processes, how alterations in these networks contribute to complex traits, such as human diseases, and where and how in the disease network one should target to optimally inhibit the disease phenotypes, such as tumor growth.
Computational statistics.
Scientific computing.
- Methods for high-throughput drug combination screening and synergy scoring (2018) Cancer Systems Biology Liye He, Evgeny Kulesskiy, Jani Saarela, Laura Turunen, Krister Wennerberg, Tero Aittokallio, Jing Tang
(A3 Vertaisarvioitu kirjan tai muun kokoomateoksen osa) - Novel activities of safe-in-human broad-spectrum antiviral agents (2018)
- Antiviral Research
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - Patient-Customized Drug Combination Prediction and Testing for T-cell Prolymphocytic Leukemia Patients (2018)
- Cancer Research
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells (2018)
- Science Translational Medicine
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - Secreted frizzled-related protein 2 (SFRP2) expression promotes lesion proliferation via canonical WNT signaling and indicates lesion borders in extraovarian endometriosis (2018)
- Human Reproduction
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - Susceptibility of low-density lipoprotein particles to aggregate depends on particle lipidome, ismodifiable, and associates with future cardiovascular deaths (2018)
- European Heart Journal
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - A community challenge for inferring genetic predictors of gene essentialities through analysis of a functional screen of cancer cell lines (2017)
- Cell Systems
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - Computational-experimental approach to drug-target interaction mapping: A case study on kinase inhibitors (2017)
- PLoS Computational Biology
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - C-SPADE: a web-tool for interactive analysis and visualization of drug screening experiments through compound-specific bioactivity dendrograms (2017)
- Nucleic Acids Research
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - Early metabolic markers identify potential targets for the prevention of type 2 diabetes (2017)
- Diabetologia
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä )



